Riskpilot← Back to searchSign inGet full accessFERRING PHARMACEUTICALS A/S
A/SActiveCVR 16313440Amager Strandvej 405Research and experimental development on natural sciences and engineering · NACE 7210Est. 1992590 employees
Revenue 2024
DKK 1,7B
+16% vs 2023
EBITDA margin
7.9%
+13% vs 2023
Equity ratio
48.0%
Financial strength
Net profit 2024
DKK 76,9M
+15% vs 2023
| Revenue | DKK 1,7B | +16% |
| EBITDA | DKK 133,3M | +13% |
| Net profit | DKK 76,9M | +15% |
| Total assets | DKK 554,5M | -5% |
| Equity | DKK 266,2M | +41% |
| Employees | 590 | — |
Legal name
FERRING PHARMACEUTICALS A/S
CVR number
16313440
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1. august 1992
Share capital
DKK 500.000
Employees
590 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af et bestyrelsesmedlem i forening med en direktør eller af to direktører i forening
Company purpose
Selskabets formål er forskning og udvikling af farmaceutiske produkter for selskaber i Ferring koncernen.
Address
Amager Strandvej 405
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.102.920 | 1.206.882 | 1.269.951 | 1.225.924 | 1.332.355 | 1.401.012 | 1.380.192 | 1.051.468 | 1.005.468 | 1.261.432 | 1.457.509 | 1.690.294 |
| Staff expenses | -343.012 | -363.669 | -384.381 | -403.241 | -468.012 | -438.907 | -0 | -0 | -145.824 | -548.186 | -589.536 | -677.285 |
| EBITDA | 74.565 | 79.521 | 88.024 | 85.935 | 88.490 | 74.420 | 82.026 | 75.226 | 54.035 | 97.748 | 118.185 | 133.251 |
| Depreciation & amort. | -17.327 | -15.967 | -19.294 | -20.602 | -18.990 | -0 | -23.653 | -18.679 | -0 | -31.208 | -29.229 | -30.089 |
| EBIT | 57.238 | 63.554 | 68.730 | 65.333 | 69.500 | 74.420 | 58.373 | 56.547 | 54.035 | 66.540 | 88.956 | 103.162 |
| Net financials | 1.199 | -185 | -1.720 | -501 | 636 | -2.850 | -9.309 | -3.796 | -1.976 | -2.595 | -2.721 | -4.190 |
| Profit before tax | 58.437 | 63.369 | 67.010 | 64.832 | 70.136 | 71.570 | 49.064 | 52.751 | 52.059 | 63.945 | 86.235 | 98.972 |
| Tax | 14.607 | 15.519 | 15.389 | 14.507 | 15.448 | 15.440 | 10.783 | 11.823 | 11.885 | 11.568 | 19.125 | 22.082 |
| Net profit | 43.830 | 47.850 | 51.621 | 50.325 | 54.688 | 56.130 | 38.281 | 40.928 | 40.174 | 52.377 | 67.110 | 76.890 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 297.742 | 317.926 | 285.673 | 353.042 | 376.926 | 397.931 | 378.172 | 381.839 | 472.880 | 485.671 | 586.405 | 554.485 |
| Equity | 117.621 | 109.471 | 86.092 | 97.417 | 112.105 | 118.235 | 106.516 | 79.444 | 69.618 | 121.995 | 189.325 | 266.214 |
| Long-term debt | 0 | -6.872 | -9.360 | -10.346 | -9.179 | 0 | 0 | 0 | 125.000 | 100.000 | 75.000 | 0 |
| Short-term debt | 175.188 | 201.583 | 190.221 | 245.279 | 255.642 | 270.940 | 263.994 | 294.410 | 269.084 | 255.819 | 315.813 | 282.477 |
| Total debt | 175.188 | 201.583 | 190.221 | 245.279 | 255.642 | 270.940 | 263.994 | 294.410 | 394.084 | 355.819 | 390.813 | 282.477 |
EBITDA margin
7.9%
This company
15.8%
Market median
-50% vs market
20132024
Equity ratio
48.0%
This company
38.2%
Market median
+26% vs market
20132024
Return on equity
28.9%
This company
18.4%
Market median
+57% vs market
20132024
Net profit margin
4.5%
This company
8.1%
Market median
-44% vs market
20132024
Asset turnover
3.05×
This company
1.12×
Market median
+172% vs market
20132024
Debt / equity
1.08×
This company
0.62×
Market median
-74% vs market
20132024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BW Management | Management | 2021 | — | — |
KG Management | Management | 2023 | — | — |
JT Management | Management | 2025 | — | — |
AH Management | Management | 2024 | — | — |
EW Management | Management | 1992 | — | — |
ÅS Management | Management | 1992 | — | — |
ET | Audit | 1992 | — | — |
PR Management | Management | 2005 | — | — |
CP Management | Management | 1998 | — | — |
JV Audit | Audit | 1992 | — | — |
KF Management | Management | 2021 | — | — |
JP Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
LM Management | Management | 2023 | — | — |
TV Management | Management | 2025 | — | — |
IT Management | Management | 2026 | — | — |
ML Management | Management | 1992 | — | — |
PE Management | Management | 1992 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2005 | — | — | |
| Chairman | 1992 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 1998 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2005 | — | — | |
| Board of Directors | 1998 | — | — | |
| Board of Directors | 1992 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 1997 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of FERRING PHARMACEUTICALS A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bolette Wildt | Management | 0 companies |
| Klaus Grønbæk Jakobsen | Management | 0 companies |
| Jesper Thomsen | Management | 0 companies |
| Anette Hedegaard Østergaard | Management | 0 companies |
| Eva Wolf Paulsen | Management | 0 companies |
| Åke Stefan Warin | Management | 0 companies |
| Erik Tronborg Andersen | Audit | 0 companies |
| Pascal Rene Olivier Danglas | Management | 0 companies |
| Christiaan Paul Thomas | Management | 0 companies |
| John Voigt | Audit | 0 companies |
| Kim Fonager Jensen | Management | 0 companies |
| Jan Peutzfeldt | Chief Executive Officer | 0 companies |
| Lene Melchiorsen | Management | 0 companies |
| Tamara Vukmirovic | Management | 0 companies |
| Ingbritt Tolstrup Birk | Management | 0 companies |
| Mats Lundwall | Management | 0 companies |
| Per Emil Hasselbalch Stakemann | Management | 0 companies |
| Ole Kjerulf-Jensen | Chairman | 0 companies |
| Ulf Svejgaard Poulsen | Chairman | 0 companies |
| Armin Metzger | Board of Directors | 0 companies |
| Jeffrey David Hobbs | Board of Directors | 0 companies |
| Per Gunnar Falk | Chairman | 0 companies |
| Pierre Yves Berclaz | Board of Directors | 0 companies |
| Jean-Frederic Paulsen | Board of Directors | 0 companies |
| Marianne Kock | Chairman | 0 companies |
| Dag Frederik Arfst Paulsen | Board of Directors | 0 companies |
| Jean Louis Junien | Board of Directors | 0 companies |
| Hans Christian Galst | Board of Directors | 0 companies |